![]() |
Medical Policy | ||
| Subject: Partial Left Ventriculectomy | |||
| Policy #: SURG.00005 | Current Effective Date: | 11/13/2006 | |
| Status: Reviewed | Last Review Date: | 09/14/2006 | |
|
Description/Scope
This policy addresses partial left ventriculectomy and other surgical ventricular remodeling procedures. Partial left ventriculectomy (PLV) is a surgical procedure aimed at improving the hemodynamic status of patients with end-stage congestive heart failure (CHF) by directly reducing left ventricular size. This surgical approach to the treatment of CHF (also known as the Batista procedure, cardio-reduction, or left ventricular remodeling surgery) is primarily directed at patients with an underlying dilated cardiomyopathy awaiting cardiac transplantation.
Surgical ventricular remodeling/restoration procedures refer to other techniques designed to restore or remodel the left ventricle to its normal shape and/or size and may also be referred to as ventricular remodeling, left ventricular reconstruction, endoventricular circular patch plasty, surgical anterior ventricular endocardial restoration (SAVER), or the Dor procedure after Vincent Dor, MD.
This policy also addresses another surgical procedure closely aligned with ventricular restoration and ventriculectomy which is called dynamic cardiomyoplasty. This surgical procedure involves wrapping skeletal muscle tissue around the diseased ventricle which is then electrically stimulated to beat in synchrony with the heart, and is purported to thereby improve ventricular functioning.
Policy Statement
Investigational/Not Medically Necessary:
Partial left ventriculectomy (PLV) is considered investigational/not medically necessary in all cases.
Other methods of remodeling or reshaping of the cardiac ventricles to reduce ventricle size with or without surgical removal, (e.g., ventricular remodeling or reshaping procedures using ventricular wrapping, piercing, or clasping techniques) are considered investigational/not medically necessary in all cases.
Rationale
Partial Left Ventriculectomy (PLV) As an example of the published literature, Franco-Cereceda and colleagues reported on the 1- and 3-year outcomes of 62 patients with dilated cardiomyopathy who underwent partial left ventriculectomy. At the time of surgery, all patients were either in New York Heart Association functional Class III or IV. Survival was 80% and 60% at one and three years after surgery, and freedom from failure was 49% and 26%, respectively. Although 80% of the patients were alive at one year, this survival was achieved with the aggressive use of ventricular assist devices and transplantation as a salvage therapy. The authors concluded that partial left ventriculectomy is not a predictable reliable alternative to transplantation. Further investigations may be warranted, focusing on the use of the procedure as a bridge to transplant, or its use in those not considered candidates for transplantation (Franco-Cereceda, 2001). In 2003, the results of the Third International Registry Report were published, including data through 2002. This report noted that the incidence of left ventriculectomy reached a peak by 1998 and was largely abandoned by 2000, except in Asia, where experienced institutions continue to perform the procedure in patients in better condition with preserved myocardial contractility (Kawaguchi, 2003). Surgical Ventricular Restoration (SVR) Athanasuleas and colleagues from the RESTORE Group, reported on early and 3-year outcomes in 662 patients who underwent SVR following anterior myocardial infarction during the period of January 1998 to July 2000 (Athanasuleas, 2002). In addition to SVR, patients also concomitantly underwent CABG (92%), mitral repair (22%), and mitral replacement (3%). The authors reported overall mortality during hospitalization was 7.7%; postoperative ejection fractions increased from 29.7% ± 11.3% to 40.0% ± 12.3% (P <. 05). The survival rate and freedom from hospitalization for heart failure at three years was 89.4% ± 1.3% and 88.7% respectively. In a separate publication on 439 patients from the RESTORE Group, Athanasuleas, et al. reported outcomes improved in patients with lower patient age, higher ejection fractions and lack of need for mitral valve replacement (Athanasuleas, 2001). Mickleborough, et al. reported on 285 patients who underwent SVR by a single surgeon for Class III or IV congestive heart failure, angina or ventricular tachyarrhythmia during the period of 1983 to 2002 (Mickleborough, 2004). In addition to SVR, patients also concomitantly underwent CABG (93%), patch septoplasty (22%), arrhythmia ablation (41%), mitral repair (3%), and mitral replacement (3%). SVR was performed on the beating heart in 7% of patients. The authors reported hospital mortality of 2.8%; postoperative ejection fractions increased 10% ± 9% from 24% ± 11% (p<.000) and symptom class in 140 patients improved 1.3 ± 1.1 functional class per patient. Patients were followed up for up to 19 years (mean, 63 ± 48 months), and overall actuarial survival was reported as 92%, 82%, and 62% at 1, 5 and 10 years respectively. The authors suggested wall-thinning should be used as a criterion for patient selection. Bolooki and colleagues reported on 157 patients that underwent SVR by a single surgeon for Class III or IV congestive heart failure, angina, ventricular tachyarrhythmia or myocardial infarction using three operative methods during the period of 1979 to 2000 (Bolooki, 2003). SVR procedures consisted of radical aneurysm resection and linear closure (n=65), septal dyskinesis reinforced with patch septoplasty (n = 70), or ventriculotomy closure with an intracavitary oval patch (n = 22). The authors reported hospital mortality of 16%. The mean preoperative ejection fraction was 28% ± 0.9%. Patients were followed up for up to 22 years, and overall actuarial survival was reported as 53%, 30%, and 18% at 5, 10 and 15 years respectively. The authors found factors improving long-term survival included SVR with intraventricular patch repair and ejection fraction of 26% or greater preoperatively. Sartipy, et al reported on 101 patients who underwent SVR using the Dor procedure at a single center for Class III or IV congestive heart failure, angina and ventricular tachyarrhythmia during the period of 1994 to 2004 (Sartipy, 2005). In addition to SVR, patients also concomitantly underwent CABG (98%), arrhythmia ablation (52%) and mitral valve procedure (29%). The authors reported early mortality (within 30 days of operation) was 7.9%; and left ventricular ejection fractions increased from 27% ± 9.9% to 33% ± 9.3% postoperatively. Patients were followed up 4.4 ± 2.8 years, and overall actuarial survival was reported as 88%, 79%, and 65% at 1, 3 and 5 years respectively. Summary In January 2002, a randomized multicenter international clinical trial on the Surgical Treatment of Ischemic Heart Failure (STICH) was initiated to compare medical therapy with CABG and/or SVR for patients with congestive heart failure and coronary heart disease (Clinical Trials.gov). The STICH trial is sponsored by the National Heart, Lung, and Blood Institute and will recruit 2,800 patients with heart failure, left ventricular ejection fraction < 35, and coronary artery disease amenable to CABG at 50 clinical sites. Patients with extensive anterior ischemia assigned to the surgical arm of the study will be further randomized to CABG surgery alone versus bypass surgery plus SVR. Completion of the trial is expected in December 2008. Background/Overview
Surgical Ventricular Restoration (SVR)
Additional techniques of ventricular reshaping include, but are not limited, to:
As of the date of this annual review update (September 14, 2006), the Acorn CorCap™ Cardiac Support Device (Acorn Cardiovascular, St. Paul, MN) and the Myosplint® device (Myocor, Maple Grove, MN) have not received FDA approval because the safety and efficacy of these devices has not yet been established in the published literature. Both devices are currently limited to investigational use in the United States.
Definitions
Partial Left Ventriculectomy (also known as the Batista procedure): a surgical procedure that reduces the size of the left ventricle by resecting (removing) a portion of the left ventricle, the pumping chamber of the heart that delivers blood to the body. This is typically done in an attempt to relieve some of the symptoms of severe congestive heart failure and is usually done in conjunction with additional cardiac surgical procedures, such as mitral valve annuloplasty or replacement.
Surgical Ventricular Restoration (also known as the Dor procedure): a surgical procedure that involves an incision into the left ventricle to exclude, but not remove, the damaged area. A remodeling device is then temporarily inserted into the ventricle around which the heart wall is then stretched, thereby reducing the diameter and restoring the shape of the left ventricle. Thereafter, the device is removed, and the opening is closed with sutures and/or a patch.
Dynamic Cardiomyoplasty: a surgical procedure in which a latissimus dorsi muscle flap is transposed into the chest and wrapped around the ventricles of the failing heart. This skeletal muscle flap is then electrically stimulated to contract in synchrony with ventricular pumping of the heart. Researchers have proposed that this muscle wrap may provide an external constraint that reduces progressive ventricular dilatation and remodeling, thereby decreasing wall tension in the ventricle and improving ventricular function.
Coding
The following codes for treatments and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member. When services are Investigational/Not Medically Necessary:
CPT
ICD-9 Procedure
ICD-9 Diagnosis
References
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
Web Sites for Additional Information
Index
Batista Procedure
Policy History
|
||||||||||||||||||||||||||||||||||||
|
Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan. ©CPT Only - American Medical Association |